{"id":10604,"date":"2013-01-27T22:45:15","date_gmt":"2013-01-27T22:45:15","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/biocon-eyes-rs-100-cr-from-psoriasis-drug-in-next-4-yrs\/"},"modified":"2013-01-27T22:45:15","modified_gmt":"2013-01-27T22:45:15","slug":"biocon-eyes-rs-100-cr-from-psoriasis-drug-in-next-4-yrs","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/biocon-eyes-rs-100-cr-from-psoriasis-drug-in-next-4-yrs\/","title":{"rendered":"Biocon eyes Rs 100 cr from psoriasis drug in next 4 yrs"},"content":{"rendered":"<p><p>Biocon eyes Rs 100 cr from psoriasis drug in next 4 yrs                            The company plans to launch the product during second        quarter of the current year                            Press Trust of India \/ New Delhi Jan 25, 2013, 14:40 IST                            <\/p>\n<p>    Biotechnology firm Biocon today said it plans to launch skin disease    drug under the brand Alzumab in the country in the current year    and aims to garner Rs 100 crore in sales in the next four    years.  <\/p>\n<p>    \"We expect it (Alzumab) to be a Rs 100 crore product in next    four years,\" Biocon Chairman and Managing Director Kiran    Mazumdar-Shaw told reporters in a conference call.  <\/p>\n<p>    Shaw said that the company invested \"little less than Rs 100    crore on developing the product\" and added the company was    confident that \"we will recover it\".  <\/p>\n<p>    Earlier this year, the company had received approval from drug    controller (DCGI) to market 'Itolizumab', used in the treatment    of psoriasis. It would be launched under the brand name,    Alzumab.  <\/p>\n<p>    The global Psoriasis market size is estimated to cross $8    billion by 2016.  <\/p>\n<p>    A novel biologic indicated for the treatment of Moderate-    to-Severe Psoriasis, Alzumab will be marketed by Biocon's    immunotherapy division, the company had said earlier.  <\/p>\n<p>    The product would be manufactured and formulated as an infusion    drug at Biocon's biopharma manufacturing facility at Biocon    Park, Bangalore.  <\/p>\n<p>    When asked about her views on compulsory licensing issue, Shaw    said on a personal level she does not favour the law.  <\/p>\n<p>    \"It should be the last option rather than the first,\" she said.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Continue reading here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.business-standard.com\/india\/news\/biocon-eyes-rs-100-crpsoriasis-drug-in-next-4-yrs\/204003\/on\" title=\"Biocon eyes Rs 100 cr from psoriasis drug in next 4 yrs\">Biocon eyes Rs 100 cr from psoriasis drug in next 4 yrs<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Biocon eyes Rs 100 cr from psoriasis drug in next 4 yrs The company plans to launch the product during second quarter of the current year Press Trust of India \/ New Delhi Jan 25, 2013, 14:40 IST Biotechnology firm Biocon today said it plans to launch skin disease drug under the brand Alzumab in the country in the current year and aims to garner Rs 100 crore in sales in the next four years.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/psoriasis\/biocon-eyes-rs-100-cr-from-psoriasis-drug-in-next-4-yrs\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-10604","post","type-post","status-publish","format-standard","hentry","category-psoriasis"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/10604"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=10604"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/10604\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=10604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=10604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=10604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}